AMSTERDAM/ZURICH, Dec 1 (Reuters) - Dutch biotech firm Crucell (CRCL.AS: Quote, Profile, Research) announced a 591 million Swiss franc ($449.4 million) bid for Berna Biotech (BBIN.S: Quote, Profile, Research) on Thursday, offering a premium based on its hopes for Berna's vaccines business.
